Safety of intraoperative chemotherapy with 5-FU for colorectal cancer patients receiving curative resection: A randomized, multicenter, prospective, phase III IOCCRC trial (IOCCRC).

• DOI: 10.1200/jco.2017.35.15_suppl.e15002
• Publication Date: 2018-09-06T15:43:08Z
• Authors: Rong-xin Zhang; Jun-zhong Lin; Gong Chen; Li-ren LI; Zhen-hai LU; Pei-Rong Ding; Xiao Jun Wu; Desen Wan; Zhi-zhong Pan
• Keywords: 03 medical and health sciences; 0302 clinical medicine; 3. Good health

e15002 Background: The safety and efficacy of intraoperative chemotherapy in colorectal cancer have not yet been extensively investigated. This randomized control trial was designed to compare the combination with surgical resection those traditional alone. Patients Methods: From January 2011 2016, 696 patients were enrolled this study: 341 randomly assigned plus surgery group receive (portal vein, intraluminal, intraperitoneal resection), whereas 344 undergo Eleven withdrew consent. Surgical complications side effects compared between two groups. Results: Intraoperative did increase rate complications, no severe chemotherapy-associated observed. There significant differences length hospital stay (8.31 vs. 7.98 days, P = 0.138), (170.4 167.0 min, 0.526), antibiotic use (2.28 2.15 0.322), or drain usage (6.37 6.16 0.387) Four each groups experienced anastomotic leakage underwent a second operation (1.2% 1.2%, 0.99). deaths within 90 days after group, one patient died (0% 0.3%, decrease who received postoperative adjuvant (29.3% 30.2%, 0.795). Conclusions: can be safely performed during surgery; however, follow-up is necessary for better assessment its efficacy. Register Number: NCT01465451. Clinical information: